BCA
LGND icon

Berman Capital Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Berman Capital Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$1K Buy
22
+14
+175% +$1.08K ﹤0.01% 1902
2021
Q2 		$0 Hold
8
– – ﹤0.01% 1975
2021
Q1 		$0 Buy
+8
New +$756 ﹤0.01% 1838
2020
Q2 		– Sell
-32
Closed -$1K – 1724
2020
Q1 		$1K Sell
32
-50
-61% -$2.83K ﹤0.01% 1323
2019
Q4 		$5K Hold
82
– – ﹤0.01% 978
2019
Q3 		$5K Buy
82
+52
+173% +$3.27K ﹤0.01% 945
2019
Q2 		$2K Sell
30
-5
-14% -$368 ﹤0.01% 1206
2019
Q1 		$2K Buy
35
+25
+250% +$1.89K ﹤0.01% 1104
2018
Q4 		$0 Buy
+10
New +$1.07K ﹤0.01% 1195

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Berman Capital Advisors's LGND Position: Q3 2021 in Review

Berman Capital Advisors increased its Ligand Pharmaceuticals (LGND) stake by 175% in Q3 2021, buying an estimated $1.08K and bringing the position to 22 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #1902.

Berman Capital Advisors first reported a position in LGND in Q4 2018 and has held it in 9 quarters since. The position peaked at $5K in Q4 2019. 207 funds tracked by Wall St. Rank hold LGND as of Q3 2021.

  • Berman Capital Advisors held 22 shares of Ligand Pharmaceuticals worth $1K as of Q3 2021.
  • Berman Capital Advisors bought 14 Ligand Pharmaceuticals shares in Q3 2021, an estimated $1.08K.
  • Ligand Pharmaceuticals made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #1902 holding.
  • Berman Capital Advisors first reported a position in Ligand Pharmaceuticals in Q4 2018 and has held it in 9 quarters since.
  • Berman Capital Advisors's Ligand Pharmaceuticals position peaked at $5K in Q4 2019.
  • 207 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.